Surgical resection is the most important therapeutic option, and the role of adjuvant radiotherapy and chemotherapy in high-risk patients is well established.2–5 Recently, vorasidenib, an IDH1 and IDH2 inhibitor, has been shown to significantly increase MRI-based progression-free survival and delay time to next intervention in non-enhancing grade 2 gliomas after surgery.6 This evidence concerns the gene IDH1 and central nervous system cancer.